IHL (ASX) Ann: IHL commences IHL-675 (ARDS) animal study

Originally posted by MickeyMantle536: ↑

In my opinion (and that’s all it is) two things are clear to me.

1. There are many posters without a background in medical research or medical patents which makes it difficult to critique parts of the business fairly as they don’t have an appreciation for their complexity. Yet here they are marking off days on the calendar like it’s counting down to Christmas and speaking in condescending tones about what could be done better.

2. Most posters on this thread have probably also never met Sud Agarwal or the other board members otherwise they might hold a different view about what they’ve managed to achieve in such a short period of time and how significant the economic opportunity actually is.

If either of the above applies then why discuss something in a negative way, particularly as it’s potentially an uninformed opinion that is also counterproductive to your own investment.

As for speaking to shareholders, I disagree. The company would only discuss public information so the issue is not the content but the interpretation that is subsequently presented on HC as fact, when perhaps it also included that posters own opinion.

I think we both agree on the massive opportunity and I’m sufficiently fluent in the science to appreciate how fast these guys have moved.

Expand

Excellent post MM agree with your comments . The board have moved very quickly and strategically placed to company to do extremely well . We have stated it before but worthwhile repeating that the they have moved very quickly particularly so given the pandemic and the technical nature of the space it is in and are set to fill a need in the ARDS space .

I do not see the point of speculation on something that we are by the most part uninformed on . It is clear they have solid fundamentals which are potential game changers with world wide application on success of the trials . In my view we need to be patient and allow it to develop as the board has skin in the game are working vigorously to achieve their objectives to make this company a big pharma play . Most of us would have no idea what it takes and how difficult to build a company in this space - so let the Board do their thing which from where I sit they are doing extremely well .

Massive opportunity and they have not put a foot wrong in my view . If investors have an issue with time or they are rsik averse that is a matter for them to determine what they do but these businesses take time to build and I am happy to wait as I see huge potential here . IMO